- Home
- SAFE vs ESPR Comparison
SAFE vs ESPR Comparison
Compare SAFE & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SAFE | ESPR |
|---|---|---|
| Founded | 2016 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 987.4M | 898.5M |
| IPO Year | 2017 | 2013 |
Fundamental Metrics
Financial Performance| Metric | SAFE | ESPR |
|---|---|---|
| Price | $14.12 | $3.14 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 10 | 6 |
| Target Price | ★ $18.80 | $6.67 |
| AVG Volume (30 Days) | 429.5K | ★ 5.4M |
| Earning Date | 02-12-2026 | 03-03-2026 |
| Dividend Yield | ★ 4.73% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.57 | N/A |
| Revenue | ★ $398,968,000.00 | $303,802,000.00 |
| Revenue This Year | $0.88 | $26.11 |
| Revenue Next Year | $3.64 | N/A |
| P/E Ratio | $9.54 | ★ N/A |
| Revenue Growth | ★ 2.96 | 2.83 |
| 52 Week Low | $12.76 | $0.69 |
| 52 Week High | $19.53 | $4.18 |
Technical Indicators
Market Signals| Indicator | SAFE | ESPR |
|---|---|---|
| Relative Strength Index (RSI) | 45.58 | 39.82 |
| Support Level | $14.51 | $3.00 |
| Resistance Level | $15.31 | $3.21 |
| Average True Range (ATR) | 0.48 | 0.22 |
| MACD | -0.01 | -0.07 |
| Stochastic Oscillator | 35.41 | 21.29 |
Price Performance
Historical ComparisonAbout SAFE Safehold Inc. New
Safehold Inc is a REIT that operates its business by acquiring, managing, and capitalizing ground leases. Ground leases are long-term contracts between the landlord (the Company) and a tenant or leaseholder. Ground leases generally represent ownership of the land underlying commercial real estate projects that are net leased by the fee owner of the land to the owners/operators of the real estate projects built thereon.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.